Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study

被引：0
作者：
Immacolata Tartaglione
Raffaella Origa
Antonis Kattamis
Michael Pfeilstöcker
Sibel Gunes
Susanne Crowe
Niamh Fagan
Beatrice Vincenzi
Giovan Battista Ruffo
机构：
[1] University of Campania Luigi Vanvitelli,Department of Woman, Child and of General and Specialist Surgery
[2] Ospedale Pediatrico Microcitemico “A.Cao,Division of Pediatric Hematology
[3] ” A.O. “G.Brotzu”,Oncology, First Department of Pediatrics
[4] National and Kapodistrian University of Athens,Third Medical Department
[5] Hanusch Hospital,undefined
[6] Novartis Farma SPA,undefined
[7] Novartis Ireland Limited,undefined
[8] U.O.C. Ematologia e Talassemia,undefined
[9] A.O. Civico-Di Cristina-Benfratelli,undefined
来源：
Experimental Hematology & Oncology | / 9卷
关键词：
Deferasirox; Chelation; Film-coated tablet; Iron overload; Long-term; Safety; Transfusion-dependent thalassemia; Myelodysplastic syndrome;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 65 条
[1]  
Cheng WY(2018)Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets Curr Med Res Opin 34 1959-1966
[2]  
Said Q(2018)Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes Eur J Haematol 101 272-282
[3]  
Hao Y(2011)Challenges of adherence and persistence with iron chelation therapy Int J Hematol 94 453-460
[4]  
Xiao Y(2010)Beta-thalassemia Orphanet J Rare Dis. 5 11-403
[5]  
Vekeman F(2013)Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major Br J Haematol 163 400-1929
[6]  
Bobbili P(2008)Impact of compliance, ferritin and LIC on long-term trends in myocardial T2* with deferasirox Blood 112 116-144
[7]  
Kattamis A(2007)Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review Transfusion. 47 1919-181
[8]  
Aydinok Y(2019)Strategies for managing transfusional iron overload: conventional treatments and novel strategies Curr Opin Hematol 26 139-952
[9]  
Taher A(2012)Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease J Clin Pharm Ther 37 173-428
[10]  
Porter JB(2018)The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: a systematic review Am J Hematol 93 943-514
1234567